Parenchyma sparing strategy and oncological prognosis in patients with colorectal cancer liver metastases

Background: preliminary study results demonstrated parenchyma sparing surgery (PSS) as an effective approach which allowed to remove colorectal cancer (CRC) metastatic lesions within the central liver cites and increased the probability of the liver re-resections. Methods: : the prospective analysis re-evaluation of the 185 CRC patients surgical treatment has been performed. Results: an overall 5-year survival (OS) of the 185 enrolled patients was 43 ± 7%, the mean and median value for OS was 48,7 ± 1.9% and 55,2 ± 5 (95%CI: 44,4 – 66,1) months. While CRC patients OS whose metastatic lesions were predominantly located within peripheral and central liver segments was 56 ± 8% and 27 ± 9% respectively (p = 0,08). A 5-year disease-free survival rates of patients with peripheral and central liver cites metastatic lesions was 31 ± 7 % and 15 ± 7%, p = 0,12. Conclusions: : parenchyma sparing surgery should be a priority pathway for complex treatment of patients with deeply located lesions of the right liver lobe. Trial registration: study registered in https://www.researchregistry.com/browse-the-registry, № 5679.